Navigation Links
FDA Approves Labeling Change for VYVANSE(R) (lisdexamfetamine dimesylate) CII to Include Supplementary Clinical Data Supporting Efficacy at 13 Hours Postdose in Children Aged 6 to 12 with ADHD
Date:6/1/2009

ADHD symptom control demonstrated from the first time point measured (1.5 hours) through 13 hours postdose

PHILADELPHIA, June 1 /PRNewswire-FirstCall/ -- Shire plc (LSE: SHP, Nasdaq: SHPGY), the global specialty biopharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved a change to the prescribing information for its once-daily Attention Deficit Hyperactivity Disorder (ADHD) treatment VYVANSE(R) (lisdexamfetamine dimesylate) CII, to include supplemental data that demonstrated significant ADHD symptom control in children aged 6 to 12 from the first time point measured (1.5 hours) through 13 hours postdose. VYVANSE is now the first and only oral ADHD stimulant treatment to have 13-hour postdose efficacy data for pediatric patients included in its product labeling.

"Children with ADHD who still exhibit symptoms into the evening might need a treatment that provides a long duration of effect from morning, through homework and family time," said Michael Yasick, Senior Vice President of the ADHD Business Unit at Shire. "The FDA approval of this labeling change for VYVANSE provides important additional information for physicians on the duration of effect of VYVANSE and use as a once daily treatment option."

This update to the VYVANSE product labeling is based on a 13-hour analog classroom study that demonstrated improvements in behavior, inattention, and math test scores in children aged 6 to 12 from the first time point measured (1.5 hours) through the last time point assessed (13 hours) postdose. This study supports the results of a previous Phase 2 laboratory school study in which VYVANSE demonstrated ADHD symptom control from the first time point assessed (two hours postdose) with duration of efficacy up to 12 hours postdose. The adverse events in the 12-h
'/>"/>

SOURCE Shire plc
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7

Related biology technology :

1. FDA Approves Boston Scientifics Next-Generation TAXUS(R) Liberte(R) Atom(TM) Stent System
2. Arpida Annual General Meeting of Shareholders Approves All Board Proposals
3. Health Canada Approves SIMPONI(TM) (golimumab) for Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. FDA Approves Label Change for Non-Invasive Fibroid Treatment
5. FDA Approves SyntheMeds REPEL-CV(R) Adhesion Barrier for Use in Pediatric Cardiac Surgery
6. FDA Approves SYMBICORT(R) for Chronic Obstructive Pulmonary Disease (COPD)
7. FDA Approves Apidra(R) SoloSTAR(R) - a Prefilled Disposable Insulin Pen
8. European Commission Approves EFIENT(R) (prasugrel) for Patients with Acute Coronary Syndrome Undergoing PCI
9. Encouraging high-risk research: DFG approves funding for 2 new Reinhart Koselleck projects
10. FDA Approves ULORIC(R) (febuxostat) for the Chronic Management of Hyperuricemia in Patients with Gout
11. FDA Approves Clinical Studies of a Novel Anti-Cancer Drug Developed by Italian Researchers

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/25/2009)..., MARKHAM,ON,Nov.25/PRNewswire/-Cytochromatod...dofDirectors.Dr.MoldtwillreplaceMr.UlrikSporkasthe...ofBoardmembersremainsunchangedatsixmembers. ,, ...ookforwardtobenefitingfromhisexperienceandguidance...ingCKD-focusedspecialtypharmaceuticalcompany,"stat...
(Date:11/25/2009)..., NEWYORK,Nov.25/PRNewswire/--Reportlinker.co...nitscatalogue: ,, BrazilBioethanolMarketAnalys...er.com/p0165503/Brazil-Bioethanol-Market-Analysis-...MarketAnalysisandForecaststo2013 ,, Summary ,...oftheglobalbioethanolmarketandtheBrazilbioethanolm...
(Date:11/24/2009)... This release is available in German . , W...tion cards: RFID tags (Radio Frequency Identificat...day life. They make it possible to label objects o...requency. The appropriate scanner can read and pro... can be affixed to goods under production conditio...
(Date:11/24/2009)... Ambassador to also Visit ...r 24, 2009 -- , , ,Who: David Appia, French Ambass...d CEO of the Invest in France Agency, , , , ,What... to discuss recent pro-business initiatives adopte...al and academic landscape for innovation and devel...
Breaking Biology Technology:Cytochroma Announces Appointment of Peter Moldt to Board of Directors 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 2Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 3Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 4Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 5Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 6Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 7Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 8Reportlinker Adds Brazil Bioethanol Market Analysis and Forecasts to 2013 9Intelligence inside metal components 2
...x, Inc.,(Nasdaq: MEDX ) today announced that it h...amount from its licensing partner, Centocor, Inc.,...pplication to the European,Medicines Agency reques...tment of rheumatoid arthritis, psoriatic arthritis...n anti-TNF monoclonal antibody that was generated ...
...y setup and launch..., WAYLAND, Mass., March 20 ...rmaceutical clinical trials software, announces th...R/IVRS platform for phase,II-IV studies. Trident,s...,leaps ahead of legacy IVRS technologies and promi...oductivity, and ease-of-use to the straining,globa...
... NexGen,Biofuels Ltd. (OTC:NXGNF) announced today ...hares have been approved for quotation on the,OTC-... a development stage company that is currently see...sel plants and blending assets in,the United State...t, http://www.nexgenbiofuels.net ., Safe Harbor: ...
Other Biology Technology:Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 2Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis 3Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 2Tourtellotte's New Trident IWR(TM) Eliminates 12-Week Study Setup Lead Time for Clinical Trials 3
(Date:11/23/2009)... Mass. November 23, 2009 Applied mathematicians ...sta lancifolia ), a characteristic long leaf with ...pples along the edges. The simple cause of the lil...m bending during differential growthwas revealed b...am ribbons. , Haiyi Liang, a postdoctoral studen...
(Date:11/23/2009)... Current research suggests that a common oral bac...ated report by Nichols et al, "Unique Lipids from ...TLR2 Ligands Capable of Enhancing Autoimmunity," a... Journal of Pathology . , Multiple sclerosis (MS...rain and spinal cord, affects nearly 1 in 700 peop...
(Date:11/23/2009)...ovember 16, 2009 -- A USDOE and USDA study conclud...opland, and cropland pasture could be converted fr...sses, such as switchgrass, from which biomass coul...nomically viable production of a perennial grass m...omass are removed annually is expected to require ...
Breaking Biology News(10 mins):The cause behind the characteristic shape of a long leaf revealed 2Factors from common human bacteria may trigger multiple sclerosis 2Switchgrass produces biomass efficiently 2Sakayu Shimizu of Kyoto University recipient of 2009 Enzyme Engineering Award 9960 1Sakayu Shimizu of Kyoto University recipient of 2009 Enzyme Engineering Award 9960 2Regulatory role of key molecule discovered at Hebrew U 9958 1MedTrust Online Surpasses 5 000 Registered Users and Adds Dr Henry Friedman to Oncology Advisory Board 14120 1MedTrust Online Surpasses 5 000 Registered Users and Adds Dr Henry Friedman to Oncology Advisory Board 14120 2
...Federal scientists have developed a vaccine that p...us. They also have created a technique for identif... that could help contain future pandemic flu strai...say, to understanding and preventing the recurrenc... pandemic and to protecting against virulent flu s...
...Human rhinovirus (HRV), the leading cause of most ...nsplant patients, leading to progressive respirato...ere part of a group of 11 transplant patients who ...ion from HRV in both the upper and lower airways, ...only upper airway tissue. , The research appears i...
...A protein known to be a key component of the glue ...king them apart and promoting their movement when ... researchers at Mayo Clinic have found. , The stud...ournal of Cell Biology, helps illuminate the very ...cancer that makes the disease difficult to treat, ...
Other Biology News:Experimental vaccine protects mice against deadly 1918 flu virus 2Experimental vaccine protects mice against deadly 1918 flu virus 3Experimental vaccine protects mice against deadly 1918 flu virus 4Common cold virus leads to death in lung transplant patients 2Two-faced protein can stop metastasis or promote it, researchers say 2Two-faced protein can stop metastasis or promote it, researchers say 3
Mouse Anti-Human QPRT Monoclonal Antibody, Unconjugated, Clone 5D11 from ABR-Affinity BioReagents
BD FACSArray bioanalyzer from BD Biosciences - Immunocytometry Systems
Agarose, Type C from Calbiochem
Chicken Anti-Human QPRT Polyclonal Antibody, Unconjugated from ProSci, Inc
Biology Products: